MiNK Therapeutics reports early Phase 2 data for agenT-797 in severe hypoxemic pneumonia trial

Lab analyses from blood and lung fluid suggested better infection control, lower inflammation, immune recovery, tissue repair, and pulmonary recovery.

No major serious adverse events were attributed to agenT-797 in the initial patients.

Enrollment continues in Lviv; U.S. sites are opening; additional data are expected in early 2027.

MiNK Therapeutics presented early Day 28 observations from an ongoing randomized Phase 2 trial of agenT-797 in severe hypoxemic pneumonia.

First treated patients were alive at the endpoint, with clinical signs consistent with improved breathing support needs and more stable circulation.